CytoSorbents Corporation (CTSO)

[techxen]

CTSO has been struggling for years to advance HemoDefend for pRBC to an FDA trial. The company has also repeatedly said they would look to out-license HemoDefend for pRBC which has not occurred. From the company's comments it appears they are continuing to run the research and development for both of the grant funded HemoDefend-BGA™ (Universal Plasma) and HemoDefend-RBC™ (pRBC) programs but are unlikely to make real progress advancing the RBC product to a trial in the near future. This is because it is a lower priority than the current STAR-T trial. So I would not expect to see any licensing deal or revenue coming from this program even in 2022.